

Date: 02.08.2025

To,  
Department of Listing Operations  
National Stock Exchange of India Limited  
'Exchange Plaza' .C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai -400 051

**Sub: Intimation of In-Principle Approval for Migration of Jeena Sikho Lifecare Limited from NSE SME Platform to NSE Main Board and BSE Main Board.**

Dear Sir / Madam,

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that Jeena Sikho Lifecare Limited has received In-Principle Approvals from both National Stock Exchange of India Limited (NSE) and BSE Limited for the migration of its equity shares from the SME Platform (NSE Emerge) to the Main Board of both the stock exchanges on **July 23, 2025 & August 01, 2025** respectively.

Please find enclosed herewith a copy of the In-principle approval letters of the BSE and NSE.

Kindly take the above information on your records and oblige.

Thanking You,

**Yours Faithfully,**  
**For and on behalf of Jeena Sikho Lifecare Limited**

**Manish Grover**  
**Managing Director**  
**DIN: 07557886**  
**Place: Zirakpur, Punjab**

## **JEENA SIKHO LIFECARE LIMITED**

120+ AYURVEDA CLINICS & HOSPITALS | FREEDOM FROM 2D DISEASES & DRUGS

**Registered Office Address:**

SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,  
Punjab-140604, 01762-513185  
CIN NO.: L52601PB2017PLC046545

**Corporate Office Address:**

B-26, Opp. Metro Pillar No. 223, Rohtak Road,  
New Multan Nagar, Delhi - 110056  
Email ID: cs@jeenasikho.com | www.jeenasikho.com

LOADL-Migration\PJ\IP\210\2025-26

August 1, 2025

The Company Secretary  
**JEENA SIKHO LIFECARE LIMITED**  
SCO 11 First Floor, Kalgidhar Enclave,  
Mohali, Zirakpur, Punjab-140604

Dear Sir/ Madam,

**Re: In-principle Approval for Listing of Equity Shares from NSE Emerge to BSE Mainboard of the Exchange through Direct Listing.**

We refer to your application dated June 23, 2025, and further submissions, seeking permission for listing of the equity shares of your Company on the Exchange, under the Direct Listing route.

We are pleased to inform you that the same was considered by the Internal Regulatory Oversight And Review Group.

Accordingly, the Exchange is pleased to grant its in-principle approval to the Company's application for listing & trading its equity shares on the BSE Mainboard Platform under direct listing. You are advised to complete the following formalities for listing of securities of the Company:

1. Letter of application for listing of shares on Main Board.
2. Listing Agreement as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. Latest Share holding pattern as per format provided by SEBI vide its circular no. CIR/CFD/CMD/13/2015 dated November 30, 2015 and financials as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and payment of applicable fees.

Kindly forward us the above-mentioned documents / information at the earliest to enable us to process the matter. You are requested to note that this approval is valid for a period of **45** days from the date of this letter.

Yours faithfully,  
For BSE Limited



**Hardik Bhuta**  
Assistant Vice President



**Parag Jain**  
Manager

Ref: NSE/LIST/266

July 23, 2025

The Company Secretary  
Jeena Sikho Lifecare Limited

Dear Sir/Madam,

**Re: In-principle approval for migration of trading in the equity shares of the company from SME Platform (EMERGE) to Main Board.**

We are in receipt of your application regarding in-principle approval for migration of trading in the 124300730 equity shares of Rs. 2/-each of the company from SME Platform (EMERGE) to Main Board in terms of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018.

In this regard, the Exchange is pleased to grant in-principle approval for proposed migration of trading in the equity shares of the company from SME Platform (EMERGE) to Main Board.

Further, the Company shall ensure submission of financial results in accordance with Reg. 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which inter-alia states that the listed entity shall, subsequent to the listing, submit its financial results for the quarter or the financial year immediately succeeding the period for which the financial statements have been disclosed in the offer document for the initial public offer, within the timeline specified in clause (a) or clause (d) of Regulation 33(3), as the case may be, or within 21 days from the date of its listing, whichever is later.

The company shall ensure submission of financial results in accordance with Reg. 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 if listed after the end of quarter but on or before due date for submission of said financial results.

Kindly note that the Exchange will issue final approval for migration of trading in the equity shares of the company from SME Platform (EMERGE) to Main Board on submission of listing application including equity listing agreement.

“Kindly note, this Exchange letter should not be construed as approval under any other Act /Regulation/rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any.”

This In-principle approval is valid for a period of 45 days from the date of issuance of this letter.

Yours faithfully,  
For National Stock Exchange of India Limited

Dipti Chinchkhede  
Senior Manager